Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients
Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR...
Gespeichert in:
| Veröffentlicht in: | Pathology oncology research 2018-07, Vol.24 (3), p.631-640 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 640 |
|---|---|
| container_issue | 3 |
| container_start_page | 631 |
| container_title | Pathology oncology research |
| container_volume | 24 |
| creator | Giaginis, Constantinos Sampani, Anastasia Kotta-Loizou, Iolly Giannopoulou, Ioanna Danas, Eugene Politi, Ekaterini Tsourouflis, Gerasimos Kouraklis, Gregorios Patsouris, Efstratios Keramopoulos, Antonios Nakopoulou, Lydia Theocharis, Stamatios |
| description | Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells’ proliferative capacity and overall and disease-free patients’ survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (
p
= 0.0234 and
p
= 0.0361, respectively), being more frequently observed in ER negative cases (
p
= 0.0208). High COX-2 expression was negatively associated with histological (
p
|
| doi_str_mv | 10.1007/s12253-017-0288-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1929107088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1929107088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-428157f4180eee55b5a409b122bf4975c8d0a723067cf4f71fe2d7d32bfa30ac3</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EoqXwAFyQJS7lYLCdeJ0ct6uFrVSpq6pI3CzHmYRUG3vxOAu8Ew-JtykgkDiN5fn-f0bzE_JS8LeCc_0OhZSqYFxoxmVVMfGInApVSCYrrh_ntxQ1K2u1OCHPEO941izqxVNykmFeVbo4JT_WOzjYBC3dTGzp09CDpzfgYJ9CpOeb6eYNXX_bR0AcgqcD0iVicMO95OuQPtPbaczksu_vmQP4XKj1Ld2G_L-NofcBs66ZEvUhzaLV9Scm_zL29NIf7NGAXkSwmOjKRjf4MFq6tWkAn_A5edLZHcKLh3pGPr5f36427Or6w-VqecVcKVRipayE0l0pKg4ASjXKlrxu8rGarqy1clXLrZYFX2jXlZ0WHchWt0Vu24JbV5yR89l3H8OXCTCZcUAHu531ECY0opa14DqfMKOv_0HvwhR93s5IXqq60HlKpsRMuRgQI3RmH4fRxu9GcHOM0sxRmhylOUZpRNa8enCemhHa34pf2WVAzgDmlu8h_hn9f9eftUCqng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2045937067</pqid></control><display><type>article</type><title>Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients</title><source>SpringerLink Journals</source><creator>Giaginis, Constantinos ; Sampani, Anastasia ; Kotta-Loizou, Iolly ; Giannopoulou, Ioanna ; Danas, Eugene ; Politi, Ekaterini ; Tsourouflis, Gerasimos ; Kouraklis, Gregorios ; Patsouris, Efstratios ; Keramopoulos, Antonios ; Nakopoulou, Lydia ; Theocharis, Stamatios</creator><creatorcontrib>Giaginis, Constantinos ; Sampani, Anastasia ; Kotta-Loizou, Iolly ; Giannopoulou, Ioanna ; Danas, Eugene ; Politi, Ekaterini ; Tsourouflis, Gerasimos ; Kouraklis, Gregorios ; Patsouris, Efstratios ; Keramopoulos, Antonios ; Nakopoulou, Lydia ; Theocharis, Stamatios</creatorcontrib><description>Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells’ proliferative capacity and overall and disease-free patients’ survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (
p
= 0.0234 and
p
= 0.0361, respectively), being more frequently observed in ER negative cases (
p
= 0.0208). High COX-2 expression was negatively associated with histological (
p
< 0.0001) and nuclear (
p
= 0.0033) grade and tumor cells’ proliferative rate (
p
= 0.0015), being more frequently observed in luminal-A compared to other molecular subtypes (
p
= 0.0221). High HuR expression was associated with poor overall and disease-free patients’ survival at both univariate (log-rank test,
p
= 0.0092 and
p
= 0.0004, respectively) and multivariate (Cox-regression analysis,
p
= 0.0223 and
p
= 0.0004, respectively) level. On the other hand, high COX-2 expression was associated with favorable overall and disease-free patients’ survival merely at univariate level (log-rank test,
p
= 0.0389 and
p
= 0.0154, respectively). HuR expression was not associated with COX-2 expression (Spearman
R
= 0.1489,
p
= 0.1032). The present data support evidence that HuR is associated with tumor aggressiveness and poor prognosis in breast carcinoma, reinforcing its potential as promising therapeutic target in this type of neoplasia.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-017-0288-1</identifier><identifier>PMID: 28808873</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Antigens ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast carcinoma ; Cancer Research ; Cyclooxygenase-2 ; Epidermal growth factor ; ErbB-2 protein ; Estrogen receptors ; HuR protein ; Immunology ; Invasiveness ; Medical prognosis ; Molecular chains ; Oncology ; Original Article ; Paraffin ; Pathology ; Progesterone ; Prognosis ; Rank tests ; Regression analysis ; Ribonucleic acid ; RNA ; RNA-binding protein ; Therapeutic applications ; Tumor cells</subject><ispartof>Pathology oncology research, 2018-07, Vol.24 (3), p.631-640</ispartof><rights>Arányi Lajos Foundation 2017</rights><rights>Pathology & Oncology Research is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-428157f4180eee55b5a409b122bf4975c8d0a723067cf4f71fe2d7d32bfa30ac3</citedby><cites>FETCH-LOGICAL-c415t-428157f4180eee55b5a409b122bf4975c8d0a723067cf4f71fe2d7d32bfa30ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-017-0288-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-017-0288-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28808873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giaginis, Constantinos</creatorcontrib><creatorcontrib>Sampani, Anastasia</creatorcontrib><creatorcontrib>Kotta-Loizou, Iolly</creatorcontrib><creatorcontrib>Giannopoulou, Ioanna</creatorcontrib><creatorcontrib>Danas, Eugene</creatorcontrib><creatorcontrib>Politi, Ekaterini</creatorcontrib><creatorcontrib>Tsourouflis, Gerasimos</creatorcontrib><creatorcontrib>Kouraklis, Gregorios</creatorcontrib><creatorcontrib>Patsouris, Efstratios</creatorcontrib><creatorcontrib>Keramopoulos, Antonios</creatorcontrib><creatorcontrib>Nakopoulou, Lydia</creatorcontrib><creatorcontrib>Theocharis, Stamatios</creatorcontrib><title>Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells’ proliferative capacity and overall and disease-free patients’ survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (
p
= 0.0234 and
p
= 0.0361, respectively), being more frequently observed in ER negative cases (
p
= 0.0208). High COX-2 expression was negatively associated with histological (
p
< 0.0001) and nuclear (
p
= 0.0033) grade and tumor cells’ proliferative rate (
p
= 0.0015), being more frequently observed in luminal-A compared to other molecular subtypes (
p
= 0.0221). High HuR expression was associated with poor overall and disease-free patients’ survival at both univariate (log-rank test,
p
= 0.0092 and
p
= 0.0004, respectively) and multivariate (Cox-regression analysis,
p
= 0.0223 and
p
= 0.0004, respectively) level. On the other hand, high COX-2 expression was associated with favorable overall and disease-free patients’ survival merely at univariate level (log-rank test,
p
= 0.0389 and
p
= 0.0154, respectively). HuR expression was not associated with COX-2 expression (Spearman
R
= 0.1489,
p
= 0.1032). The present data support evidence that HuR is associated with tumor aggressiveness and poor prognosis in breast carcinoma, reinforcing its potential as promising therapeutic target in this type of neoplasia.</description><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast carcinoma</subject><subject>Cancer Research</subject><subject>Cyclooxygenase-2</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Estrogen receptors</subject><subject>HuR protein</subject><subject>Immunology</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Molecular chains</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Paraffin</subject><subject>Pathology</subject><subject>Progesterone</subject><subject>Prognosis</subject><subject>Rank tests</subject><subject>Regression analysis</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA-binding protein</subject><subject>Therapeutic applications</subject><subject>Tumor cells</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcFu1DAQhi0EoqXwAFyQJS7lYLCdeJ0ct6uFrVSpq6pI3CzHmYRUG3vxOAu8Ew-JtykgkDiN5fn-f0bzE_JS8LeCc_0OhZSqYFxoxmVVMfGInApVSCYrrh_ntxQ1K2u1OCHPEO941izqxVNykmFeVbo4JT_WOzjYBC3dTGzp09CDpzfgYJ9CpOeb6eYNXX_bR0AcgqcD0iVicMO95OuQPtPbaczksu_vmQP4XKj1Ld2G_L-NofcBs66ZEvUhzaLV9Scm_zL29NIf7NGAXkSwmOjKRjf4MFq6tWkAn_A5edLZHcKLh3pGPr5f36427Or6w-VqecVcKVRipayE0l0pKg4ASjXKlrxu8rGarqy1clXLrZYFX2jXlZ0WHchWt0Vu24JbV5yR89l3H8OXCTCZcUAHu531ECY0opa14DqfMKOv_0HvwhR93s5IXqq60HlKpsRMuRgQI3RmH4fRxu9GcHOM0sxRmhylOUZpRNa8enCemhHa34pf2WVAzgDmlu8h_hn9f9eftUCqng</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Giaginis, Constantinos</creator><creator>Sampani, Anastasia</creator><creator>Kotta-Loizou, Iolly</creator><creator>Giannopoulou, Ioanna</creator><creator>Danas, Eugene</creator><creator>Politi, Ekaterini</creator><creator>Tsourouflis, Gerasimos</creator><creator>Kouraklis, Gregorios</creator><creator>Patsouris, Efstratios</creator><creator>Keramopoulos, Antonios</creator><creator>Nakopoulou, Lydia</creator><creator>Theocharis, Stamatios</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180701</creationdate><title>Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients</title><author>Giaginis, Constantinos ; Sampani, Anastasia ; Kotta-Loizou, Iolly ; Giannopoulou, Ioanna ; Danas, Eugene ; Politi, Ekaterini ; Tsourouflis, Gerasimos ; Kouraklis, Gregorios ; Patsouris, Efstratios ; Keramopoulos, Antonios ; Nakopoulou, Lydia ; Theocharis, Stamatios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-428157f4180eee55b5a409b122bf4975c8d0a723067cf4f71fe2d7d32bfa30ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast carcinoma</topic><topic>Cancer Research</topic><topic>Cyclooxygenase-2</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Estrogen receptors</topic><topic>HuR protein</topic><topic>Immunology</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Molecular chains</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Paraffin</topic><topic>Pathology</topic><topic>Progesterone</topic><topic>Prognosis</topic><topic>Rank tests</topic><topic>Regression analysis</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA-binding protein</topic><topic>Therapeutic applications</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giaginis, Constantinos</creatorcontrib><creatorcontrib>Sampani, Anastasia</creatorcontrib><creatorcontrib>Kotta-Loizou, Iolly</creatorcontrib><creatorcontrib>Giannopoulou, Ioanna</creatorcontrib><creatorcontrib>Danas, Eugene</creatorcontrib><creatorcontrib>Politi, Ekaterini</creatorcontrib><creatorcontrib>Tsourouflis, Gerasimos</creatorcontrib><creatorcontrib>Kouraklis, Gregorios</creatorcontrib><creatorcontrib>Patsouris, Efstratios</creatorcontrib><creatorcontrib>Keramopoulos, Antonios</creatorcontrib><creatorcontrib>Nakopoulou, Lydia</creatorcontrib><creatorcontrib>Theocharis, Stamatios</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giaginis, Constantinos</au><au>Sampani, Anastasia</au><au>Kotta-Loizou, Iolly</au><au>Giannopoulou, Ioanna</au><au>Danas, Eugene</au><au>Politi, Ekaterini</au><au>Tsourouflis, Gerasimos</au><au>Kouraklis, Gregorios</au><au>Patsouris, Efstratios</au><au>Keramopoulos, Antonios</au><au>Nakopoulou, Lydia</au><au>Theocharis, Stamatios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>24</volume><issue>3</issue><spage>631</spage><epage>640</epage><pages>631-640</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells’ proliferative capacity and overall and disease-free patients’ survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (
p
= 0.0234 and
p
= 0.0361, respectively), being more frequently observed in ER negative cases (
p
= 0.0208). High COX-2 expression was negatively associated with histological (
p
< 0.0001) and nuclear (
p
= 0.0033) grade and tumor cells’ proliferative rate (
p
= 0.0015), being more frequently observed in luminal-A compared to other molecular subtypes (
p
= 0.0221). High HuR expression was associated with poor overall and disease-free patients’ survival at both univariate (log-rank test,
p
= 0.0092 and
p
= 0.0004, respectively) and multivariate (Cox-regression analysis,
p
= 0.0223 and
p
= 0.0004, respectively) level. On the other hand, high COX-2 expression was associated with favorable overall and disease-free patients’ survival merely at univariate level (log-rank test,
p
= 0.0389 and
p
= 0.0154, respectively). HuR expression was not associated with COX-2 expression (Spearman
R
= 0.1489,
p
= 0.1032). The present data support evidence that HuR is associated with tumor aggressiveness and poor prognosis in breast carcinoma, reinforcing its potential as promising therapeutic target in this type of neoplasia.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>28808873</pmid><doi>10.1007/s12253-017-0288-1</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1219-4956 |
| ispartof | Pathology oncology research, 2018-07, Vol.24 (3), p.631-640 |
| issn | 1219-4956 1532-2807 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1929107088 |
| source | SpringerLink Journals |
| subjects | Antigens Biomedical and Life Sciences Biomedicine Breast cancer Breast carcinoma Cancer Research Cyclooxygenase-2 Epidermal growth factor ErbB-2 protein Estrogen receptors HuR protein Immunology Invasiveness Medical prognosis Molecular chains Oncology Original Article Paraffin Pathology Progesterone Prognosis Rank tests Regression analysis Ribonucleic acid RNA RNA-binding protein Therapeutic applications Tumor cells |
| title | Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T09%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20Hu-Antigen%20Receptor%20(HuR)%20Expression%20is%20Associated%20with%20Tumor%20Aggressiveness%20and%20Poor%20Prognosis%20but%20not%20with%20COX-2%20Expression%20in%20Invasive%20Breast%20Carcinoma%20Patients&rft.jtitle=Pathology%20oncology%20research&rft.au=Giaginis,%20Constantinos&rft.date=2018-07-01&rft.volume=24&rft.issue=3&rft.spage=631&rft.epage=640&rft.pages=631-640&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-017-0288-1&rft_dat=%3Cproquest_cross%3E1929107088%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2045937067&rft_id=info:pmid/28808873&rfr_iscdi=true |